Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 25;64(3):582-589.
doi: 10.1093/jrr/rrad009.

Effectiveness of proton beam therapy for liver oligometastatic recurrence in patients with postoperative esophagus cancer

Hisashi Yamaguchi  1   2 , Takahiro Kato  2 , Michitaka Honda  1   3 , Koichi Hamada  1   4 , Ichiro Seto  2 , Takuya Tominaga  2 , Yoshiaki Takagawa  1   2 , Kanako Takayama  2 , Motohisa Suzuki  2 , Yasuhiro Kikuchi  2 , Yasushi Teranishi  3 , Masao Murakami  2
Affiliations

Effectiveness of proton beam therapy for liver oligometastatic recurrence in patients with postoperative esophagus cancer

Hisashi Yamaguchi et al. J Radiat Res. .

Abstract

There are several reports of hepatic resection for postoperative hepatic metastatic recurrence of esophageal cancer. However, it is unclear whether surgery is the best local treatment for liver metastases. Thus, this study aimed to retrospectively analyze proton beam therapy (PBT) for postoperative liver metastatic recurrence of esophageal cancer without extrahepatic lesions and examine outcomes and adverse events. This single-center historical cohort study selected patients who underwent PBT at our proton therapy center between 2012 and 2018. The patients were selected based on the following criteria: primary esophagus carcinoma was resection and metachronous liver oligometastasis recurrence without extrahepatic tumors and no more than three liver metastases. This study included seven males with a median age of 66 (range, 58-78) years, and 15 lesions were included in the study. The median tumor size was 22.6 (7-55.3) mm. The most frequent dose was 72.6 Gy relative biological effect (RBE)/22 fractions (fr) for four lesions and 64 Gy (RBE)/8 fr for four lesions. The median survival time was 35.5 (13.2-119.4) months. The 1-, 2- and 3-year overall survival (OS) rates were 100%, 57.1% and 42.9%, respectively. The median progression-free survival (PFS) time was 8.7 (1.2-44.1) months. The 1-, 2- and 3-year PFS rates were 28.6%. The 1-, 2- and 3-year local control (LC) rates were 100%. No grade ≥4 radiation-induced adverse events (AEs) were observed. We conclude that PBT can be considered an alternative to hepatic resection for recurrent liver metastases postoperative esophageal cancer.

Keywords: esophagus cancer; liver metastatic; proton therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflicts of interest to report.

Figures

Fig. 1
Fig. 1
Kaplan–Meier plot of OS), PFS and LC. (a) OS and (b) PFS curves for all treated patients; (c) LC curves for all treated lesions.
See this image and copyright information in PMC

References

    1. Ichida H, Imamura H, Yoshimoto J et al. Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma. World J Surg 2013;37:398–407. - PubMed
    1. Liu J, Wei Z, Wang Y et al. Hepatic resection for post-operative solitary liver metastasis from oesophageal squamous cell carcinoma. ANZ J Surg 2018;88:E252–6. - PubMed
    1. Fukumitsu N, Okumura T, Takizawa D et al. Proton beam therapy for liver metastases from gastric cancer. J Radiat Res 2017;58:357–62. - PMC - PubMed
    1. Yamaguchi H, Honda M, Hamada K et al. The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients. Jpn J Clin Oncol 2020;50:903–8. - PubMed
    1. Fukumitsu N, Okumura T, Takizawa D et al. Proton beam therapy for metastatic liver tumors. Radiother Oncol 2015;117:322–7. - PubMed